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Abstract
Background: The attenuated Yellow fever (YF) 17D vaccine virus is one of the safest and most effective viral
vaccines administered to humans, in which it elicits a polyvalent immune response. Herein, we used the YF 17D
backbone to express a Trypanosoma cruzi CD8+ T cell epitope from the Amastigote Surface Protein 2 (ASP-2) to
provide further evidence for the potential of this virus to express foreign epitopes. The TEWETGQI CD8+ T cell
epitope was cloned and expressed based on two different genomic insertion sites: in the fg loop of the viral
Envelope protein and the protease cleavage site between the NS2B and NS3. We investigated whether the site of
expression had any influence on immunogenicity of this model epitope.
Results: Recombinant viruses replicated similarly to vaccine virus YF 17D in cell culture and remained
genetically stable after several serial passages in Vero cells. Immunogenicity studies revealed that both
recombinant viruses elicited neutralizing antibodies to the YF virus as well as generated an antigen-specific
gamma interferon mediated T-cell response in immunized mice. The recombinant viruses displayed a more
attenuated phenotype than the YF 17DD vaccine counterpart in mice. Vaccination of a mouse lineage highly
susceptible to infection by T. cruzi with a homologous prime-boost regimen of recombinant YF viruses elicited
TEWETGQI specific CD8+ T cells which might be correlated with a delay in mouse mortality after a challenge
with a lethal dose of T. cruzi.
Conclusions: We conclude that the YF 17D platform is useful to express T. cruzi (Protozoan) antigens at different
functional regions of its genome with minimal reduction of vector fitness. In addition, the model T. cruzi epitope
expressed at different regions of the YF 17D genome elicited a similar T cell-based immune response, suggesting
that both expression sites are useful. However, the epitope as such is not protective and it remains to be seen
whether expression of larger domains of ASP-2, which include the TEWETGQI epitope, will elicit better T-CD8+
responses to the latter. It is likely that additional antigens and recombinant virus formulations will be necessary to
generate a protective response.
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Background
The Yellow Fever Virus (YF) is a member of the Flavi-
virus genus and Flaviviridae family. The YF genome
consists of a single positive-stranded RNA molecule
with an approximate 11 kb length encoding a single
polyprotein precursor. The YF polyprotein is processed
by cellular and viral proteases generating the viral struc-
tural proteins which compose the virus particle, namely
capsid (C), membrane (M) and its precursor (prM) plus
envelope (E) in addition to the non-structural proteins
NS1, NS2A, NS2B, NS3, NS4A, NS4B and NS5, posses-
sing different roles in viral replication [1].
The attenuated yellow fever (YF) 17D vaccine is one
of the safest and most effective attenuated viral vaccines
available for human immunization. Its production,
under strict quality control procedures, has been admi-
nistered to man since the late 1930’s [2]. A single prime
dose promotes an excellent seroconversion rate in more
than 90% of all vaccinees and can provide immunity for
more than 30 years, yielding a robust and persistent
neutralizing antibody response as a primary adaptive
defense [3]. A role for cell-mediated immunity driven by
a single YF 17D virus vaccine dose was first proposed
[4] and in addition confirmed with the identification of
YF-specific human effector and memory T CD8+ cells
addressed to E, NS1, NS2B and NS3 proteins of YF 17D
[5-7]. However, understanding of the mechanisms by
which the YF 17D virus triggers immune response is
only now being unveiled and includes a multiple of
virus component interactions with the immune system.
The YF 17D virus was shown to induce a polyvalent
immune response due to its capacity to infect and acti-
vate different subsets of human dendritic cells, via Toll-
like receptors (TLRs), resulting in the production of
pro-inflammatory cytokines, such as interferon a (IFN-
a) and other interleukins (IL-12p40, IL-6), thus the
basis to generate the marked adaptive immune response
succeeding YF 17D virus vaccination [8]. Adaptive
immune response to YF 17D virus immunization is
characterized by a considerable expansion of specific
activated T CD8+ cells together with a mixed T helper
cell (Th1 and Th2) cytokine profile controlled by stimu-
lation of different TLRs [9,10]. These results indicate a
relevant immunological starting point for the characteri-
zation of recombinant YF 17D viruses as new vaccine
candidates, suggesting they resemble YF 17D in its nat-
ural immune response.
For more than ten years, YF 17D has been developed
as a recombinant viral vector to express other flavivirus
proteins, such as the prM/E of Japanese Encephalitis
Virus, Dengue Virus and West Nile Virus [11]. While
these 17D recombinants are based on the substitution of
equivalent YF 17D genes, other antigens from unrelated
pathogens have also recently been successfully expressed
and delivered by the recombinant YF 17D as alternative
strategies for genetic manipulation of the YF 17D
genome. One of the previous studies described a recom-
binant YF 17D virus containing an ovalbumin immuno-
dominant cytotoxic T cell epitope, expressed at the
junction of NS2B and NS3 genes, which was cleaved of
the polyprotein due to the duplication of viral protease
NS2B/3 cleavage sites [12]. The same YF cloning strat-
egy was employed in a subsequent work to express a
Plasmodium yoelli CD8+ T cell epitope [13]. Both of
these studies demonstrated that YF 17D recombinant
viruses do protect vaccinated mice against lethal chal-
lenge with malignant melanoma cells or the malaria
parasite, respectively. Another possibility of YF 17D
engineering was developed by our group through three-
dimensional structure modeling analysis of the YF E
protein with the identification of two expression sites
permissive to heterologous insertions [14,15]. A number
of recombinant YF 17D viruses that express T cell and
humoral epitope of the Plasmodium spp CS protein
inserted at the fg loop have been constructed. These
viruses were quite stable through serial passages in cul-
tured vertebrate cells and also retained attenuation for
mice and monkeys [16]. The epitope expression in the E
protein seems to be an interesting approach, since there
have been recent reports that this protein elicits domi-
nant immune responses corresponding either to MHC
class I or class II antigens [17,18].
In this study, we have evaluated the expression of an
immunodominant epitope of ASP-2 (amastigote surface
protein 2) of Trypanosoma cruzi, the ethiological agent
of Chagas disease, by the YF 17D virus. T.cruzi is an
obligate intracellular protozoan parasite. Despite recent
efforts to reduce transmission in Latin America, Chagas
disease still affects near 13 million people, provoking
more than 15,000 deaths per year. Another 50 to
80 million people are at risk of infection [19]. Recently,
the occurrence of microepidemics due to food borne
transmission has been reported [20]. In this regard, new
strategies should be adopted in order to develop an
efficacious prophylaxis for Chagas disease.
ASP-2 is a 83 kDa surface protein of T. cruzi intracellu-
lar amastigote forms, recognized by specific cytotoxic T
lymphocytes of mice and man [21,22]. It has been
described as one of the best antigen targets for a Chagas
vaccine [23-25]. Previous reports on immunization of
highly susceptible As/n mice with an ASP-2 recombinant
plasmid, protein or viral vectors have exhibited protec-
tion against a lethal T. cruzi infection in conjunction with
Th1 adjuvants or heterologous prime-boost regimens.
However, the depletion of CD8+ T cells in vaccinated
animals prior the challenge with T.cruzi caused high
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mortality rates. It was demonstrated that the protective
CD8 + T lymphocytes were directed to the H-2Kk-
restricted immunodominant epitope TEWETGQI posi-
tioned from 320 to 327 amino acid residues of ASP-2
[25]. Although the immunization with TEWETGQI eli-
cited similar numbers of peptide-specific IFN-g secreting
cells as did recombinant ASP-2 protein fragments con-
taining the immunodominant octapeptide, protective
immunity after T.cruzi challenge could be only elicited
by the immunization with the TEWETGQI epitope in
the context of a ASP-2 protein fragments [26]. The lack
of protective immunity observed following immunization
TEWETGQI was correlated with a lower priming of
memory peptide-specific CD8+ T cells [26].
YF-17D virus is one the most efficient human vaccine
virus ever obtained. It is also an outstanding inducer of
CD8+ T cell immune responses [6]. We aimed at defin-
ing whether in the context of the YF 17D vector the
immunodominant ASP-2 epitope, TEWETGQI, could
elicit CD8+ T cell response and protective immunity
against a lethal challenge with T. cruzi. To determine
that the TEWETGQI epitope was expressed at two dif-
ferent locations of the YF 17D genome, that is, between
NS2B and NS3 proteins and at the E protein dimer
surface.
We also intended to compare the efficacy of these two
strategies in eliciting specific T cell responses against
this T.cruzi epitope, since the cell compartments
involved in the expression and release of the foreign
epitope are distinct. The TEWETGQI epitope is
expected to be released in the cell cytoplasm when
expressed at the NS2B/NS3 site and in the ER as part of
the envelope protein, which will eventually form the
viral envelope used to assemble virus particles and exit-
ing the cell through its secretory pathway. In addition,
we characterized these recombinant viruses in terms of
replication and attenuation. Both recombinant viruses
were also evaluated in relation of their ability to induce
protection against a lethal challenge with T. cruzi .
Results
Generation of YF 17D recombinant viruses expressing a
T. cruzi T-cell epitope
To properly express the TEWETGQI epitope between
NS2B and NS3 we firstly endowed this sequence with
flanking viral protease cleavage site motif. These flank-
ing clevage sites promote the correct epitope release in
the citoplasm during viral polyprotein translation and
proteolytic processing, yielding the peptide SPTEWETG-
QIGARR (Figure 1). This recombinant virus, called
YF17D/NS2B3/Tc, was recovered after Vero cell trans-
fection indicating that the viral polyprotein was correctly
processed, resulting in viable viruses which were able to
disseminate in Vero cell culture. The insertion of the
TEWETGQI epitope in the fg loop of domain II of the
E protein did not require any additional sequence, as
previously reported elsewhere for different viruses
expressing distinct Plasmodium sp epitopes in this area
Figure 1 Schematic diagram of YF 17D virus genome organization and the corresponding insertion sites. The YF virus genome (A) is
translated in a polyprotein of 3,411 amino acids (B), which is proteolytically processed by the viral protease complex NS2B-NS3. Open arrows
indicate cleavage sites, releasing functional viral proteins in the cytosol of the cell. Dark arrows indicate host signalase cleavage sites. Open
triangle indicates furin cleavage site and dark triangle indicates unknown host protease cleavage site. TEWETGQI epitope was inserted at two
different positions (C): between f and g strands of the YF 17D virus E protein Domain II located at 482 amino acid of (left panel) or between
duplicated flanking viral protease cleavage sites (GARR/S Glycine-Alanine-Arginine-Arginine-Serine) at the junction between NS2B and NS3
proteins (open arrows; right panel) located at 1486 amino acid of the YF 17D virus polyprotein.
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of the E protein [14-16]. The recombinant viruses,
denominated YF17D/E200/Tc and YF17D/NS2B3/Tc,
produced similar post-transfection titers, around 6.0
log10 PFU/mL. The presence and integrity of the insert
in the viral genome were confirmed by nucleotide
sequencing of viral RNA extracted from the stocks.
Viral proliferation in Vero cells
The recombinant viruses, YF 17D/NS2B3/Tc and YF
17D/E200/Tc, were analyzed for their growth properties
in Vero cells in comparison to two other control viruses,
the YF 17DD vaccine virus and the parental YF 17D/
E200T3 virus [14]. Three independent experiments were
carried out with a MOI of 0.02 (Figure 2A). The peak
titer for all viruses was 72hs post-infection with the
maximum virus yields for the vaccine control virus YF
17DD (6.79 ± 0.34 log10 PFU/mL). However, the peak
titer values obtained from the parental control virus YF
17D/E200T3 (6.42 ± 0.14 log10 PFU/mL) or the recom-
binant viruses YF17D/E200/Tc (6.38 ± 0.12 log10 PFU/
mL) or YF17D/NS2B3/Tc (6.68 ± 0.12 log10 PFU/mL)
were very close to the vaccine YF 17DD virus. Hence,
the differences among them were not statistically signifi-
cant (P > 0.05, Tukey’s test). However, the yield of the
recombinant YF17D/E200/Tc up to 48 h post-infection
was lower when compared to the other viruses. Figure
2B shows reduced plaque size of both recombinant
viruses as compared to parental YF 17DD.
Epitope expression by the recombinant viruses
In order to confirm the expression of the eight amino
acid T. cruzi epitope (TEWETGQI) by the YF 17D/
E200/Tc and YF 17D/NS2B3/Tc recombinant viruses,
we performed an indirect immunofluorescence assay
using a mouse polyclonal serum against TEWETGQI
and a mouse polyclonal hyperimmune serum directed to
YF 17D (Figure 3). While the YF hyperimmune serum
could detect YF antigens in all infected Vero cell condi-
tions, the polyclonal anti-TEWETGQI antibody was
only able to stain Vero cells which were infected either
by the YF 17D/E200/Tc or YF 17D/NS2B3/Tc viruses,
suggesting the correct expression of the TEWETGQI
epitope by both recombinant viruses.
Genetic stability
To evaluate the stability of the foreign insertion
expressed by the two recombinant YF viruses, we have
performed two series of separate passages in Vero cells
per virus sample, infecting cells with a MOI of 0.02. At
the second, fifth and eighth passages we performed a
nucleotide sequencing analysis of the respective viruses.
The TEWETGQI coding sequence could be detected in
all samples, either in the intergenic NS2B/NS3 region or
the E protein fg loop, indicating that both viruses were
genetically stable. Furthermore, we plaqued the recom-
binant viruses belonging to the second, fifth and eighth
passages and no variation in plaque size was observed.
In addition, full-genome sequencing of viruses in each
above passages, failed to reveal any nucleotide differ-
ences further supporting the plaquing data.
Virus attenuation in Swiss mouse model
YF 17D viruses display a considerable degree of neuro-
virulence for mice [27]. Even though the mouse neuro-
virulence test does not predict virulence or attenuation
of YF viruses for man, it is adopted to assess the fitness
of the recombinant viruses as compared to the human
vaccine YF 17D virus. This phenotypic trait is verified
by intracerebral inoculation of Swiss mice and scoring
mortality and average survival time as exhibited in
Table 1. The recombinant viruses were significantly less
lethal than the vaccine YF 17DD virus, which killed 29
out of 30 animals with an average survival time (AST)
of 10 ± 1.8 days, in contrast to 8 out of 30 for the
YF17D/NS2B3/Tc and 1 out of 30 for YF17D/E200/Tc,
which exhibited AST values of 12 ± 4.1 days and 13 ±
0.0 days, respectively. The differences in mortality rates
across groups after 21 days were statistically significant
(logrank test; P < 0.0001). The animals inoculated
with YF17D/E200/Tc experienced a significant lower
Figure 2 Characterization of recombinant YF 17D viruses. A)
Replicative kinetics in Vero cells of recombinant viruses. YF 17D/
NS2B3/Tc (open triangles) and YF 17D/E200/Tc (black squares),
control YF 17D/E200T3 (dark gray discontinuous circles) and YF
17DD (light gray complete circles). Each time point represents the
average titer obtained from three separate experiments with the
respective standard deviations. No statistically significant differences
were found. B) Plaque morphology of YF 17DD, 17D/NS2B3/Tc and
YF17D/E200/Tc.
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mortality comparing to those inoculated with the
YF17D/NS2B3/Tc (logrank test; P < 0.0001). These
results indicate that the recombinant viruses exhibit an
increased degree of attenuation in comparison to the
17DD vaccine counterpart.
Susceptibility of A/J mice to YF 17DD virus infection
Previous studies have indicated that the A/J (H-2Kk)
mouse is an attractive model for Chagas disease prophy-
lactic studies, since this strain is highly susceptible to
infection by Trypanosoma cruzi, as are not BALB/c or
C57BL/6 lineages [28]. H-2Kk mice present parasitemic
peaks from 10th to 14th days followed by 100% of death
before the 30th day after the challenge [28]. However,
we did not know if this specific mouse lineage was sus-
ceptible to the YF 17D virus infection. For this purpose,
we vaccinated the A/J mice with two doses of the YF
17DD vaccine virus and challenged two weeks later with
an intracerebral inoculation of the same virus. The YF
17DD virus immunized mice were completely protected
against a lethal YF 17DD virus intracerebral challenge as
well as the group of animals which was vaccinated with
the recombinant YF17D/NS2B3/Tc virus (Table 2). In
contrast, the mock immunized mouse group, that was
not protected, died from the 9 to 13 day after YF 17DD
challenge.
Immunogenicity of different recombinant YF 17D virus in
A/J mice
We have next examined whether recombinant YF 17D
viruses bearing the T.cruzi epitope would elicit the char-
acteristic neutralizing antibody response. The immuniza-
tion of the A/J mice with either YF 17DD vaccine virus
or any of the recombinant viruses elicited YF neutraliz-
ing antibodies (Table 2). After the two-dose regimen,
nevertheless, the antibody neutralizing titers for the
Figure 3 Expression of the T. cruzi TEWETGQI epitope by recombinant YF17D/E200/Tc and YF17D/NS2B3/Tc viruses . Indirect
immunofluorescence assay of Vero cells infected with recombinant viruses, YF 17DD vaccine virus or not infected (Earle’s Medium 199) stained
with a mouse polyclonal hyperimmune serum to YF17D (HIYF) or polyclonal antibody directed to the TEWETGQI epitope. Second antibodies
were Alexa Fluor 488 goat anti-mouse IgG and Alexa Fluor 546 goat anti-mouse IgG for HIYF (green color) or anti-TEWETGQI (red color)
preparations, respectively.
Table 1 Swiss mouse neurovirulence of YF 17D viruses
Inoculation Dose
(log10 PFU)
Mouse challenge
% mortality (dead/tested)
AST
± SD (days)b
Controla - 0 (0/30) -
YF 17DD (vaccine) 3.0 97 (29/30) 10 ± 1.8
YF17D/NS2B3/Tc 3.0 27 (8/30)* 12 ± 4.1
YF17D/E200/Tc 3.0 3 (1/30)* 13 ± 0.0
aThe mouse control group was inoculated with only Earle’s 199 medium by the intracerebral route.
bAST, Average Survival Time ± Standard Deviation (SD).
*P < 0.05, logrank test (Mantel-Cox) test.
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recombinant viruses (1:124 for YF17D/E200/Tc virus
and 1:274 for YF17D/NS2B3/Tc virus) were lower than
those obtained with the vaccine YF 17DD virus immuni-
zation, which was 1:1,007 (P < 0.05, Tukey test). We
could not observe any significant difference in the anti-
body neutralizing titers induced by the recombinant
virus immunizations (P > 0.05, Tukey test). These data
suggest again an increased attenuation of the recombi-
nant viruses.
Vaccination with recombinant YF 17D viruses induces
IFN-g mediated-cellular immune responses
Having previously shown that recombinant YF 17D viruses
were capable of eliciting a significant neutralizing response
to YF, the next step was the analysis of the immunogeni-
city of the T.cruzi TEWETGQI epitope recombinant
viruses in A/J mice. For this purpose we evaluated by ELI-
SPOT the number of specific gamma interferon (IFN-g)
producing cells recovered from the spleen of mice that
were previously immunized or not with YF 17DD vaccine,
the two YF 17D recombinant viruses and with the T. cruzi
epitope TEWETGQI emulsified in Complete Freund’s
Adjuvant (Figure 4A and 4B) or immunized and chal-
lenged with T. cruzi (Figure 4C). First, we stimulated
splenocytes in vitro with inactivated YF 17DD virus
(Figure 4A) to assess cellular immune response against YF
structural epitopes mainly. We found that YF 17DD and
YF17D/NS2B3/Tc are specifically inducing gamma inter-
feron-cells production as compared to either Mock or
TEWETGQI-Adjuvant immunized groups (P < 0.05,
Tukey’s test). Nevertheless, YF 17D/E200/Tc virus induced
about 52 ± 41 (mean ± SD) SFC/106 cells while YF 17D/
NS2B3/Tc induced 119 ± 108 SFC/106 cells, similar to YF
17DD (136 ± 88 SFC/106 cells). Although differences
between YF17D/E200/Tc and YF 17DD immunized
groups or between recombinant groups were not statisti-
cally significant, YF17D/E200/Tc seem to be a borderline
virus since we can not statistically distinguish this immu-
nized group from Mock.
When we evaluated the specific CD8+ T cell
response due to the TEWETGQI stimulus (Figure 4B),
we detected significant differences in the number of
IFN-g producing cells (SFC) in the group vaccinated
with YF17D/NS2B3/Tc recombinant virus in compari-
son to the vaccinated YF17DD group (P < 0.05,
Tukey’s test). However, there were no statistically
significant differences among YF17D/E200/Tc,
TEWETGQI-Adjuvant and control YF17DD groups.
The YF17D/NS2B3/Tc virus elicited a mean of 151 ±
119 SFC/106 cells while the YF17D/E200/Tc virus and
TEWETGQI control groups induced 57 ± 44 and 68 ±
27 SFC/106 cells, respectively (differences between
recombinant groups and among YF17D/NS2B3/Tc and
TEWETGQI groups were significant, P < 0.05, Tukey’s
test).
Next, we evaluated specific CD8+ T cell expansion
after a T. cruzi trypomastigote challenge (Figure 4C) in
vaccinated mice. There proved to be a significant
increase in the levels of IFN-g production for both
recombinant viruses, with a mean of 1,077 ± 490 SFC/
106 cells for YF 17D/NS2B3/Tc group and 1,240 ± 514
SFC/106 cells for YF 17D/E200/Tc. The TEWETGQI-
adjuvant immunized group exhibited a mean of 999 ±
527 SFC/106 cells. Differences of these three groups
were statistically significant in contrast to the YF 17DD
group (P < 0.05, Tukey’s test). Despite the lower levels
of IFN-g producing cells induced by the YF17D/E200/Tc
in the pre-challenge tests shown above, this virus were
able to induce similar levels of IFN-g producing cells as
YF17D/NS2B3/Tc and the TEWETGQI-adjuvant groups
in post-challenge tests. There were no differences
among recombinant viruses and TEWETGQI-adjuvant
condition (P > 0.05; Tukey test).
These results clearly demonstrate that these CD8+ T
cells were primed during immunization of mice with
recombinant YF 17D viruses and expanded after
T. cruzi challenge. This expansion was 20 times higher
for YF17D/E200/Tc. Moreover, in control groups there
was no anamnestic response to TEWETGQI after a try-
pomastigote challenge as observed with the groups
immunized with the recombinant viruses (YF17D/E200/
Tc or YF17D/NS2B3/Tc).
Table 2 Immunogenicity of recombinant YF 17D viruses in A/J mice
Immunogena Animals (n) PRNT50
a Protection after YF17D challenge (%)
1 dose 2 doses
YF 17DD 15 358 ± 119 1007 ± 243 100
YF17D/E200/Tc 15 41 ± 12* 124 ± 67** NTb
YF17D/NS2B3/Tc 15 90 ± 20* 274 ± 240** 100
199 Earle’s Medium 15 < 10 < 10 -
aReciprocal of the dilution yielding 50% plaque reduction due to neutralizing antibodies in the serum analyzed. Values represent mean of three independent
experiments (pooled serum) ± standard deviation (SD). *first and **second dose titers displaying statistically significant differences related to YF17DD group (P <
0.05, Tukey’s test).
bNT; Not tested.
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Vaccination with 17D recombinant viruses does increase
mice survival time after a lethal challenge with T. cruzi
In order to establish the degree of protection induced
by immunization with YF17D recombinant viruses, we
used a challenge dose of 250 trypomastigotes of the T.
cruzi Y strain, which led to a 100% mortality rate after
23 days post-inoculation (dpi) in the A/J mice. How-
ever, the immunization with YF17D/E200/Tc or
YF17D/NS2B3/Tc viruses reduced mouse mortality
after challenge, displaying significant levels of protec-
tion as we also detected in TEWETGQI-adjuvant ani-
mals, in comparison to YF 17DD and Mock-infected
controls (P < 0.0001, logrank test) (Figure 5). Notwith-
standing, we could not observe complete mouse
protection, since only two out of fifteen (13% of
protection) survived in the YF17D/NS2B3/Tc immu-
nized group until the day 60 (Table 3). These surviving
mice displayed clinical symptoms of parasitic infection
(fever, loss of apetite, apathy), which entirely recovered
around 25 dpi (data not shown). Moreover, recombi-
nant virus groups presented an average of survival
time (AST) longer than the YF17DD group, as YF17D/
NS2B3/Tc group presented an AST of 24.8 ± 5.8 (P =
0.0005, Mann-Whitney test) and YF17D/E200/Tc
group, an AST of 23.7 ± 2.9 (P = 0.001, Mann-Whit-
ney test). No significant differences were found
between the recombinant viruses average survival
times, although YF17D/NS2B3/Tc immunization and
the TEWETGQI-adjuvant control group seems to pro-
vide a longer survival time than YF17D/E200/Tc
(Table 3).
Figure 4 ELISPOT assay for TEWETGQI-specific IFN-g secreting
cells before and after a T. cruzi challenge. Groups of A/J mice
were immunized with Mock (Earle’s 199 Medium), YF17DD virus,
recombinant viruses (YF17D/E200/Tc and YF17D/NS2B3/Tc) or with
TEWETGQI emulsified in Freund’s Adjuvant. Spleen cells were
obtained one week after the last dose (before challenge) or two
weeks after challenge. A) Spleen cells response to YF17DD stimulus
before challenge. B) Spleen cells response to TEWETGQI stimulus
before challenge. C) Spleen cells response to TEWETGQI stimulus
after challenge. Results represent IFN-g producing cells (SFC) per 106
spleen cells. Statistically significant differences (ANOVA Tukey’s test)
are shown in the graphics.
Figure 5 Kaplan-Meier survival curves. Groups were immunized
twice with medium (Mock), YF 17DD, the two recombinant viruses
or with TEWETGQI emulsified in Freund’s Adjuvant and infected or
not intraperitoneally with 250 T. cruzi bloodstream trypomastigotes.
Differences between the recombinant viruses and the YF17DD
groups were statistically significant (***P < 0.0001, logrank test).
Results represents pooled data obtained from three independent
experiments with 5 animals per group per experiment.
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Discussion
Due to the lack of a current chemotherapy to Chagas dis-
ease as other neglected disease, it is essential to develop
new strategies for its prevention. For the past decade,
several Trypanosoma cruzi antigens have been tested for
protective immunity of mice. They have included plasmid
DNA, recombinant proteins associated with several adju-
vants and bacteria or virus vectors [24,25,29,30]. How-
ever, DNA vaccine immunogenicity is not yet well
established in man, despite the fact that recombinant
protein or subunit vaccines may require the use of adju-
vant formulations certified for human use [31].
The Yellow fever vaccine virus (YF 17D) has been suc-
cessfully used as a viral platform to express antigenic
sequences from other flaviviruses [11], non-related
pathogens such as SIV [32,33], Plasmodium spp.
[13,14,16,34] and influenza [35,36]. The recombinant YF
17D viruses described here are replication-competent
viruses with advantages over other viral vectors such as
lifelong immunogenicity and no integration into the
host genome. Importantly, in our studies, we demon-
strated that pre-existing neutralizing antibodies to YF
17DD (elicited after the initial dose) did not hamper
immune responses after a second dose of vaccination, as
measured by antigen-specific IFN-g producing cells and
higher YF-specific neutralizing antibody titers.
Considering these favorable characteristics of the YF
17DD vaccine virus and based on the previous protec-
tion results reported with the antigens present in the
intracellular forms of the parasite [37], we decided to
express an epitope of T. cruzi Amastigote Surface Pro-
tein 2 (ASP-2). The selected TEWETGQI motif is an
immunodominant CD8+ T cell epitope, which binds to
the MHC class I H-2Kk molecule [25]. To express this
T.cruzi octapeptide, we employed two distinct meth-
odologies. In the first, the insertion in the intergenic
NS2B-NS3 region, it is expected to occur that, after the
proteolytic cleavage of part of viral precursor polypro-
tein mediated by the viral NS2B-NS3 proteolytic
complex, the foreign peptide will be released in cyto-
plasm and be presented by MHC class leading to CD8+
T cell activation. Using this approach, it was possible to
demonstrate that mouse vaccination with single dose of
different recombinant yellow fever viruses could pro-
mote partial or complete protection against a challenge
with a rodent malaria parasite or a lethal melanoma,
respectively. In both studies, the protection was asso-
ciated to the induction of IFNg-secreting CD8+ T cells
[12,13]. The second approach involved the epitope
expression on the surface of viral E protein, the major
flaviviral envelope protein. Besides being the main target
of viral neutralizing antibodies, several CD8+ T cell epi-
topes have been mapped in YF 17D E protein in mice,
rhesus macaques and humans [7,17,18]. Akondy and
colleagues [7] verified that more than ten percent of
total IFN-gamma producing CD8+ T cell in vaccines
were specific to epitopes present in E protein. It is con-
ceivable that processing of epitopes via MHC class I
occurs through either virion endocytosed virus particles
or ER-phagosome interaction [38].
Therefore, the expression of the TEWETGQI epitope
at two different sites of a vector known to elicit strong
CD8+ T cell immune response, with likely different
pathways for processing and presentation, was
approached in terms of its importance in protection
against challenge with live trypanosomes. This is the
first description of recombinant YF 17D viruses expres-
sing an antigen of T. cruzi, the causative agent of
Chagas disease. These recombinant viruses were charac-
terized with regard to the foreign epitope expression,
viral growth, attenuation and immunogenicity for mice.
Both viruses replicated well in Vero cells, producing
similar titers to YF 17DD at 72 hours post-infection and
were capable to maintain the heterologous epitope
insertions until at least the eighth serial passage in Vero
cells. However, insertions clearly affected viral plaque
morphology in Vero cells, when compared to the vac-
cine virus plaque phenotype. Both recombinants were
also less virulent for mice after intracerebral inoculation
than the YF 17DD vaccine virus. While YF 17DD killed
most mice, only about one third of the animals died
after the YF17D/NS2B3/Tc inoculation and a yet fewer
died with YF 17D/E200/Tc. With regard to the induc-
tion of neutralizing antibodies after only one dose, the
titers elicited by the recombinant viruses were signifi-
cantly lower than those elicited by the YF 17DD. After
the second dose, inferior titers are still evident for both
recombinant viruses. Although we could not find any
statistically difference between the recombinant viruses,
YF17D/E200/Tc seemed to induce lower titers of neu-
tralizing antibodies than YF17D/NS2B3/Tc. It is believed
that this insertion in the fg loop of the E protein may
affect the conformational change ocurring in the
Table 3 Protection of vaccinated A/J mice after a T. cruzi
challenge
Immunogen Days after challenge
live/total animals (% survival)a
AST ± SD
23dpi 40dpi 60 dpi
Mock 0/15 (0) 0/15 (0) 0/15 (0) 19.3 ± 1.4
YF 17DD 1/15 (6) 0/15 (0) 0/15 (0) 20.3 ± 1.5
YF17D/E200/Tc 10/15 (66) 0/15 (0) 0/15 (0) 23.7 ± 2.9**
YF17D/NS2B3/Tc 9/15 (60) 3/15 (20) 2/15 (13) 24.8 ± 5.8***
TEWETGQI/Adjv 5/6 (83) 1/6 (16) 0/6 (0) 29.7 ± 7.9***
aMice were immunized with medium (Mock), YF 17DD, the two recombinant
viruses or with TEWETGQI emulsified in Freund’s Adjuvant. Four weeks after
the second dose, mice were challenged i.p. with 250 bloodstream
trypomastigotes. Average survival times (AST) were significant different (***P
<0.0005, **P < 0.001, Mann Whitney test).
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trimerization of this protein at the process of fusion to
the endosome membrane which might result in a more
attenuated phenotype or increased susceptibility to viral
neutralization [16].
An unusual lineage of mice named A/J (H2-Kk) was
adopted in this work to evaluate YF immune responses
due to its high susceptibility to T. cruzi infection [28].
We observed that immunization with the YF 17DD
virus successfully protected mice of this lineage against
a YF 17DD intracerebral challenge and also elicited
titers of neutralizing antibodies against YF 17DD as
described for BALB/c mice [39]. It has already been
demonstrated that every YF viral protein is immuno-
genic and possesses CD8+ T cell epitopes [6,7]. As for
A/J mice we also demonstrate that this lineage is cap-
able of responding with specific IFN-g SFC to YF 17DD,
this result being comparable to those induced by the
two recombinant viruses.
Immunity elicited by ASP-2 is associated with a type
I response generated by IFN-g producing CD4+ and
CD8+ T cells [40,41]. High levels of IFN-g have been
associated with protection for many infections by
intracellular parasitic and viral agents [42,43]. Former
studies showed that IFN-g secretion by CD8+ T cells
was particularly important for survival of BALB/c and
C57BL/6 mice after day 14 post infection with T. cruzi
[44]. The observed levels of protection elicited by both
recombinants might be correlated with expansion of
IFN-g production by CD8+ T cells as demonstrated by
ELISPOT on day 15 after challenge. We consider this
result important as we know that any delay in CD8+ T
cell expansion (and gamma interferon production)
represents a major factor in T. cruzi infection outcome
in mice and Chagas disease in man [40,42,44]. We also
found that the period between 14 and 23 dpi is also
critical for A/J mice survival as almost all naïve (mock)
infected animals died by day 23 dpi as opposed to vac-
cinated animals. The immune response elicited by
either recombinant virus controlled incipient infection,
leading to partial protection afterwards in contrast to
the naïve group. However, more experiments would be
needed to determine whether this cellular response is
able to persist for a longer period of time after
immunization.
A plausible explanation for an incomplete protection
may be related to the fact that immunization with this
single peptide may not be sufficient to fully protect
mice against T. cruzi [44] despite TEWETGQI-specific
IFN-g producing CD8+ T cells [25]. Furthermore, low
levels of protection afforded by vaccination with T.
cruzi octapeptide correlated with a lower priming of
memory peptide-specific T cells generation [26]. In this
regard, a broader repertoire of epitopes present in a lar-
ger ASP-2 insert may be required to increase the
protection since larger portions of ASP-2, employed
either as recombinant protein or expressed by plasmids
or adenovirus vectors, in different vaccination protocols
shown to induce protection against T. cruzi challenge
in the range from 80% to 100% [25,26,30]. In addition,
the presence of other CD4+ T cell epitopes may be
essential in order to contribute to the enhancement of
the CD8+ T cell response, as observed for Chagas dis-
ease [44] or malaria [34].
Recombinant YF 17D viruses have been considered as
a promising approach for immunization against other
diseases, particularly due to its polyfunctional immune
response [9]. Since a prophylactic strategy for Chagas
disease remains to be established, our results on the
expression and immunogenicity of T. cruzi CD8+ T cell
epitope between the NS2B and NS3 proteins of the
recombinant YF 17D virus warrant further development.
Future viral formulations containing different YF con-
structs at the NS2B-3 site delivering distinct epitopes
against the same pathogen might enhance protective
responses. In addition, a YF construct that encompasses
a larger ASP-2 segment inserted between the E protein
and the nonstructural NS1 protein should also be tried
as this site seems to tolerate larger fragments, while
retaining fitness and immunogenicity [33,39].
Conclusions
We were able to express a CD8+ T cell epitope,
TEWETGQI, derived from the Trypanosoma cruzi
amastigote surface protein 2 (ASP-2) in two distinct
regions of the YF genome: in the intergenic region of
the NS2B and NS3 viral protease and at the E protein
dimer surface. Both epitope insertion methodologies
were previously characterized. They allowed the correct
processing of the viral polyprotein and did not compro-
mise viral viability, being genetically stable up to the 8th
passage. The recombinant viruses were less virulent for
mice after a intracerebral inoculation than the YF
17DD, confirming that both recombinant viruses have
an increased attenuation.
Both YF recombinant viruses elicited titers of neutra-
lizing antibodies to YF 17DD or presented protection
against an intracerebral YF challenge in A/J mice.
They were also able to elicit YF 17DD or TEWETGQI-
specific IFN-g-producing CD8+ T cells and to expand
TEWETGQI-stimulated cells vigourously after a T. cruzi
challenge. However, recombinant virus possessing the
epitope at the E protein seemed to induce significantly
lower numbers of IFN-g-producing cells than the NS2B/
NS3 recombinant virus. Although both recombinants
were able to delay mortality in T. cruzi infected mice
and to increase significantly survival, immunization with
NS2B/NS3 virus allowed a longer average survival time
than the epitope containing E protein virus. Moreover,
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NS2B/NS3 virus provided a partial mice protection up
to the 60th day after challenge.
This system is likely to be useful for a broader live
attenuated YF 17D virus-based vaccine development for
other human diseases. Besides, insertion of foreign
genes into distinct regions of flavivirus genome may also
allow further studies on immunologically protective
responses associated with specific cell-compartment har-
boring heterologous epitopes derived from other viral or
parasitic agent. It remains to be seen whether expression
of larger domains of ASP-1, which include the
TWETGQI epitope, will elicit better T-CD8+ responses
to the latter. It is likely that additional antigens and
recombinant virus formulations will be necessary to gen-
erate a protective response.
Methods
Mice
Female 4 to 6 week-old A/J mice in this study were
obtained from CECAL, Fiocruz (Rio de Janeiro, Brazil)
or purchased from CEMIB/UNICAMP. Three week-old
female Swiss mice were purchased from CEMIB/UNI-
CAMP. All animal experimentation was in accordance
with the Institutional Committee for Experimentation
and Care of Research Animals (CEUA-Fiocruz: L-0032)
guidelines.
Cell culture and vaccine virus
Vero cells (ATCC) were grown in Earle’s199 medium
supplemented with 5% fetal bovine serum (FBS). Vac-
cine sub-strain YF17DD, used in this study, was recon-
stituted in 0.5 mL of sterile water as specified by the
manufacturer’s (Bio-Manguinhos, Rio de Janeiro, Brazil).
Vaccine YF17D substrains variability and history of pas-
sages was previously described [45], [46]. Vaccine strain
YF17 D, used in this study, was reconstituted in 0.5 mL
of sterile water as specified by the manufacturer’s (Bio-
Manguinhos, Rio de Janeiro, Brazil).
Construction and recovery of parental and recombinant
viruses
The parental YF17D/E200T3 virus was constructed and
recovered as described elsewhere [14]. This virus con-
tains an Eco RV insertion site at nucleotide 1568 of the
viral genome. The strategy of insertion between the
NS2B/NS3 region was based on the approach previously
described [12] with some minor modifications. Briefly,
the plasmid pT3 containing the central portion of YF
genomic complementary DNA was mutagenized to cre-
ate a Sma I restriction site at the intergenic NS2B/NS3
region using the QuikChange II Site-Directed Mutagen-
esis Kit (Agilent Technologies) in the presence of muta-
genizing oligonucleotides containing the insertion. This
mutation inserted a CCC codon at the 4574 YF genome
position. The recovery of parental YF17D/NS2B3 virus
was made through the two-plasmid system with the
pYFE200 plasmid as a source of the ends of genomic YF
DNA as previously described [14]. To obtain the recom-
binant viruses, the plasmids pYFE200 and Sma I muta-
genized pT3, were digested with Eco RV and Sma I,
respectively to insert the TEWETGQI epitope (ASP-2
protein amino acids 320 - 327). Synthetic dephosphory-
lated oligonucleotide 5’ ACAGAATGGGAGACAGGA-
CAGATC 3’ and its complement were annealed and
ligated, into the EcoRV restriction site of pYFE200 (to
generate YF17D/E200/Tc virus) or into the Sma I site of
pYFT3 (to generate YF17D/NS2B3/Tc virus). After che-
mically competent Escherichia coli MC1061 transforma-
tion, recombinant plasmids were screened by digestion
with EcoRV (pYFE200) or Sma I (pT3) followed by
nucleotide sequencing to confirm insertion orientation.
Two sets of templates were generated by Sal I and Nsi I
cleavages and T4 DNA ligase procedure. The first con-
sisted on the ligation of the recombinant TEWETGQI
pYFE200 plasmid with the pT3 plasmid fragments. The
second was the ligation of the pE200 plasmid plus the
recombinant TEWETGQI pT3 plasmid. All templates
were linearized by Xho I digestion and submitted to in
vitro transcription by SP6 RNA polymerase (Ampli-
Scribe SP6 kit, Epicentre Technologies). The viral RNA
was transfected into Vero cells with LipofectAmine
(Invitrogen), as previously reported [14]. After the onset
of cytopathic effect, the viral supernatant was collected
and prepared for a second passage viral stock for all
subsequent experiments.
Viral growth in Vero cells
Viral proliferation curves were determined by infecting
monolayers of Vero cells at MOI of 0.02. Cells were
seeded at a density of 62,500 cell/cm2 and infected
24 hs later. Samples of the cell culture supernatant were
collected at 24-hour intervals post-infection. Viral yields
were estimated by plaque titration on Vero cells. The
different viral growth peaks were compared using the
One Way ANOVA test. The Tukey test was selected as a
posttest to compare pairs of group means. (GraphPad
Prism 5.03 Program). The differences were only consid-
ered significant when P < 0.05.
RT/PCR and sequencing
Viral RNA was extracted with Trizol LS (Invitrogen)
and used as a template for cDNA synthesis as previously
described [14]. Two sets of YF-specific synthetic oligo-
nucleotides were employed. To amplify the sequence
containing the NS2B/NS3 region, a sense primer
encompassing the genomic position 4,181 to 4,200 nt
and a reverse from 4,858 to 4,874 were utilized. The
RT-PCR fragment containing the envelope insertion site
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was obtained using the positive sense primer and the
reverse primers corresponding to nucleotides 940 to 960
and 1,781 to 1,799. After QIAquick PCR Purification
(QIAGEN), PCR products were submitted to nucleotide
sequencing as described elsewhere [39]. Nucleotide
sequences were analyzed with Chromas software version
2.3 (Technelysium Pty Ltd) and Seq-Man II software
from Lasergene package version 8.0 (DNAStar Inc.).
Genetic stability assay
Recombinant viruses were submitted to two indepen-
dent series of eight passages in Vero cells at MOI of
0.02. In the second, fifth and1) eighth passage, viral
RNA was extracted at 72 hs post-infection from the
Vero cell culture and submitted to RT/PCR and sequen-
cing as above.
Mouse neurovirulence studies
Groups of ten three-week old Swiss mice were inocu-
lated by the intra-cerebral route as previously described
[14]. Animals were followed up for 21 days and deaths
recorded. Cumulative mortality and survival curves
(Kaplan-Meyer method) were compared across groups
and formally tested using the logrank test (GraphPad
Prism 5.03 Program).
Fluorescence microscopy
Vero cells monolayers were infected at a MOI of 0.1
with Earle’s199 medium alone, control virus YF 17DD
or recombinant viruses as previously described [14]. We
adopted as primary antibodies mouse anti-TEWETGQI
or mouse hyperimmune ascitic fluid to YF 17D (ATCC).
Mouse anti-TEWETGQI antibodies were generated by
immunization of BALB/c mice with a recombinant
fusion protein containing the TEWETGQI fused to the
glutathione S-Transferase. Mice were immunized with
the 25 μg of the recombinant protein emulsified in
Complete Freund’s Adjuvant and subsequently boosted
twice with the same amount of protein emulsified in
Incomplete Freund’s Adjvant [47]. This anti-sera was
used a final dilution of 1:200. As secondary antibodies,
we used Alexa Fluor 546 goat anti-mouse IgG-Invitro-
gen or Alexa Fluor 488 goat anti-mouse IgG-Invitrogen
(diluted 1:400), according to the manufacture’s protocol.
Both preparations were treated with SlowFade-Gold
antifade reagent with DAPI (Invitrogen) and analysed by
Fluorescence Microscopy with an Olympus IX51
Inverted Microscope.
Immunogenicity of YF 17D virus in A/J mice
Groups of five 4-week old A/J mice (H-2Kk) were sub-
cutaneously injected with Medium (Mock) or with
100,000 PFU of YF 17DD virus or YF 17D recombinant
viruses on days 0 and 15. An additional group received
two doses of the TEWETGQI epitope diluted in PBS
and emulsified in Freund’s adjuvant (Sigma) according
to specifications of the manufacturer in a final concen-
tration dose of 40 μg/50 μL. Two weeks after the second
dose, mice were bled (retrorbital) and challenged intra-
cerebrally with 3,000 PFU of YF 17 D. Challenged ani-
mals were monitored for 21days and deaths recorded.
Serum samples were analyzed for antibodies YF by
the plaque-reduction neutralization test (PRNT) as
described [14]. Plaque neutralization titers were calcu-
lated as the highest dilution of antibody reducing 50% of
the input virus plaques. One-way ANOVA was used to
compare the mean titers of neutralizing antibodies of
the experimental groups. The Tukey test was selected as
a posttest to compare pairs of group means. GraphPad
Prism 5.03 Program was utilized to analyze the data.
Protection of vaccinated A/J mice against a lethal T. cruzi
challenge
To perform T. cruzi challenge assays, groups of five 4-6
week-old A/J mice were immunized with the different
viruses as described above. Four weeks after the last
dose, mice were challenged intraperitoneally with 250
bloodstream trypomastigotes of the T. cruzi Y strain.
After challenge, clinical symptoms and deaths were daily
recorded for a period of 60 days. Results represent
pooled data from three independent experiments invol-
ving five animals per group and per experiment. Cumu-
lative mortality and survival curves (Kaplan-Meyer
method) were compared across groups and formally
tested using the logrank test (GraphPad Prism 5.03
Program).
IFN-g ELISPOT assays
For the IFN-g ELISPOT assays, groups of mice were
immunized as described above, including a control
group of TEWETGQI peptide. One week after the sec-
ond dose and two weeks after T. cruzi challenge, mice
were sacrificed and the spleens removed. All assays were
carried out using BD IFN-g ELISPOT set (BD - Bios-
ciences Pharmingen, San Diego-CA). Plates were coated
with 10 μg/mL of purified anti-IFN-g and after overnight
incubation, plates were blocked with RPMI 1% FBS for
at least 2 hours at 37°C in atmosphere containing 5%
CO2. Spleen cells were removed aseptically and red
blood cells were lysed with hemolysis solution (NH4Cl
0.14 mol/L/Tris 0.017 mol/L pH 7.2). Leucocytes were
resuspended to a concentration of 2 × 105 viable cells
per mL in RPMI 1640 medium (Invitrogen) supplemen-
ted with 1 M HEPES buffer, 2 mM L-Glutamine, 5 μM
b-mercaptoethanol, 1 mM sodium pyruvate, 1% non-
essential amino acid solution, 1% (V/V) vitamin (all
from Invitrogen), 10% (V/V) Fetal Bovine Serum
(Gibco) and 50 μg/mL gentamicin. Cells were incubated
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with Medium alone, 10 μg/mL of synthetic TEWETGQI
peptide (Invitrogen), 10,000 PFU/mL of inactivated YF
17DD virus or 4 μg of concanavalin A (Sigma) diluted
in RPMI 10% FBS medium. After incubation of 48 hs at
37°C in an atmosphere containing 5% CO2, plates were
extensively washed and incubated with biotinylated anti-
IFN-g antibody (BD) followed by peroxidase-labeled
streptavidin diluted 1:800 in PBS containing 10% FBS.
After 3 hours of incubation, plates were washed with
PBS-Tween and spots were developed by adding AEC
BD substrate with cromogen (20 μl/mL) and 30% hydro-
gen peroxide solution from Sigma (1 μl/mL). Reaction
was stopped under running water and IFN-g secreting
cells that appeared as red spots were counted with an
Immunospot reader (Cellular Technology Ltd., Cleve-
land, OH) using the Immunospot Software version 3 by
the ELISPOT Platform of PDTIS/Fiocruz - Rio de
Janeiro (Lima-Junior et al., 2008). Statistical significance
of the differences was verified with One-way analysis of
variance and Tukey’s test.
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